Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. (26th August 2019)

• Record Type: Journal Article
• Authors: Satlin, Michael J; Nicolau, David P; Humphries, Romney M; Kuti, Joseph L; Campeau, Shelley A; Lewis II, James S; Weinstein, Melvin P; Jorgensen, James H
• Is Part Of: Clinical infectious diseases. Volume 70:Number 6(2020)
• Page Start: 1240
• Page End: 1246
• Publication Date: 2019-08-26
• Subjects: daptomycin -- breakpoints -- Enterococcus faecium -- CLSI; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz845
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Daptomycin is one of the few treatment options for infections caused by enterococci that are resistant to ampicillin and vancomycin, such as vancomycin-resistant Enterococcus faecium . The emergence and clinical significance of daptomycin-resistant enterococci and evolving microbiologic, pharmacokinetic-pharmacodynamic, and clinical data indicated that the pre-2019 Clinical and Laboratory Standards Institute (CLSI) susceptible-only breakpoint of ≤4 μg/mL for daptomycin and enterococci was no longer appropriate. After analyzing data that are outlined in this article, the CLSI Subcommittee on Antimicrobial Susceptibility Testing established new breakpoints for daptomycin and enterococci. For E. faecium, a susceptible dose-dependent (SDD) breakpoint of ≤4 μg/mL was established based on an increased dosage of 8–12 mg/kg/day (≥8 μg/mL-resistant). CLSI suggests infectious diseases consultation to guide daptomycin use for the SDD category. For Enterococcus faecalis and other enterococcal species, revised breakpoints of ≤2 μg/mL-susceptible, 4 μg/mL-intermediate, and ≥8 μg/mL-resistant were established based on a standard dosage of 6 mg/kg/day.